Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 71.40

-1.5%

3:19 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: emil who wrote (2207)	8/19/1998 12:21:00 AM
From: Miljenko Zuanic	Read Replies (2) of 4676

Emil: Famivirsen revenue will not be significant (at least not near term), still it may help to pay bills. Isis have to reduce R&D expenditure, or recapture and repay it by collaborations/license (new and existing). CpG IP is good example. S-oligo (with CpG motive) stimulate positive immune response. Some investor think that this immune response stimulation is main reasons for Isis drug efficiency in CMV (and Crohn's), so in their eyes this must be good. I think that this agreement is OK. BTW, I like Merck agreement. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next